This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: September 8, 2008
Last updated: September 4, 2013
Last verified: September 2013
The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.

Condition Intervention Phase
Renal Impairment Drug: YM178 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Effect of Mild, Moderate and Severe Renal Impairment on the Pharmacokinetics of YM178

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Assessment of pharmacokinetics parameters [ Time Frame: day 1 - day 6 ]

Secondary Outcome Measures:
  • Metabolite analysis [ Time Frame: day 1 - day 6 ]
  • Assessment of safety and tolerability [ Time Frame: day 1 - day 6 ]

Enrollment: 33
Study Start Date: September 2008
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1. Severe renal impairment
severe renal impairment
Drug: YM178
Other Name: mirabegron
Experimental: 2. Moderate renal impairment
moderate renal impairment
Drug: YM178
Other Name: mirabegron
Experimental: 3. Mild renal impairment
mild renal impairment
Drug: YM178
Other Name: mirabegron
Experimental: 4. Normal renal function
normal renal function
Drug: YM178
Other Name: mirabegron


Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • good health other than renal impairment
  • body mass index (BMI) between 18 and 40 kg/m2

Exclusion Criteria:

  • subject with renal impairment has not been on stable dose of concomitant medication for at least 2 weeks
  • subject has liver enzyme abnormalities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00750620

United States, California
Anaheim, California, United States, 92801
United States, Florida
Miami, Florida, United States, 33014-3616
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Central Contact Astellas Pharma Global Development
  More Information

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT00750620     History of Changes
Other Study ID Numbers: 178-CL-038
Study First Received: September 8, 2008
Last Updated: September 4, 2013

Keywords provided by Astellas Pharma Inc:
mild, moderate, and severe renal impaired subjects
normal renal function subjects
Glomerular filtration rate (GFR)
Modification of Diet in Renal Disease (MDRD) formula

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Adrenergic beta-3 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on June 23, 2017